Drugs in Dev. Musculoskeletal
Phase III
France 
Lead Product(s) : Sarilumab
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 26, 2018
Lead Product(s) : Sarilumab
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Regeneron Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GZ402662
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 16, 2017
Lead Product(s) : GZ402662
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts Ipsen’s Nda for Ultra-Rare Genetic Disorder Drug
Details : Analysis of the primary endpoint data demonstrated a 62% reduction in mean annualised new HO volume in participants treated with palovarotene versus untreated participants from a natural-history study.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation will highlight data from Ipsen’s MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 09, 2020
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Post hoc analyses showed substantial reduction (62%) in mean annualized new heterotopic ossification volume in patients with FOP who were treated with oral investigational therapy palovarotene.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted at ENDO 2020
Details : The data include a first-of-its kind study highlighting one-year data on the natural progression of FOP and the impact of heterotopic ossification (HO) on patients’ physical functioning over time.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ipsen to conduct further assessment of the complete data set and work with the regulatory authorities, based on encouraging therapeutic activity signals observed in preliminary post-hoc analyses.
Product Name : Sohonos
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2020
Lead Product(s) : Palovarotene
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 20, 2012
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 20, 2012
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
